Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:56:41.857Z.
Consensus retrieved: 2026-10-06T11:02:22.460Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:56:41.857Z.
Quote observation: 2026-10-06T14:38:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4a3a0e03002c1ec33ed026058caacdcc2374dd3411b27b5cd001974e391cfa1f
Forward PE Ratio (N/A) = Dated Quote Price ($3.87) / Consensus Forward EPS ($-2.07)
FORWARD PE RATIO
N/A
Edesa Biotech, Inc.
Market Cap
$37.23M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Edesa Biotech, Inc. (EDSA) | $37.23M | N/A |
| iTonic Holdings Ltd. (ITOC)vs › | $37.06M | N/A |
| DocGo Inc. (DCGO)vs › | $36.48M | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.42M | N/A |
| Accuray Incorporated (ARAY)vs › | $35.53M | N/A |
| Incannex Healthcare Limited (IXHL)vs › | $39.24M | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $39.28M | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.06M | N/A |
| Nephros, Inc. (NEPH)vs › | $39.63M | 23.30 |
| Elutia Inc (ELUT)vs › | $34.42M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-09-30
At the dated quote price of $3.87, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-09-30 | $-2.07 | $-2.82 – $-1.30 | 2 | n/m |
| 2028-09-30 | $-2.05 | $-2.92 – $-1.18 | 2 | n/m |
| 2029-09-30 | $-2.37 | $-2.37 – $-2.37 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
